Chemoprevention of Bladder Cancer by soybean
大豆对膀胱癌的化学预防
基本信息
- 批准号:6575544
- 负责人:
- 金额:$ 30.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-06-01 至 2007-05-31
- 项目状态:已结题
- 来源:
- 关键词:SCID mouse angiogenesis angiopoietins apoptosis biomarker bladder neoplasm cell proliferation chemoprevention cyclin dependent kinase diet therapy dietary supplements gene expression genistein immunocytochemistry microarray technology mucosa nutrition aspect of cancer nutrition related tag phytoestrogens polymerase chain reaction soybeans
项目摘要
DESCRIPTION (provided by applicant): This proposal is focused on the chemopreventive activity of soybean bioactive components on bladder cancer. The hypothesis is that increased dietary consumption of soybean bioactive components may serve as an effective nutritional regimen for the prevention of bladder cancer progression and metastasis by modulating bladder tumor angiogenesis, apoptosis and/or proliferation. The rationale for supporting this hypothesis is based on the followings: (1) Soy bioactive components exert their effects on anti-bladder cancer via both blood circulation and direct contact with the mucosa of the bladder, and (2) Our animal studies and in vivo mechanistic studies indicated that soy phytochemicals inhibited bladder tumor progression by inducing tumor cell apoptosis, inhibiting tumor proliferation and inhibiting tumor angiogenesis. In this proposal, three specific aims will be designed to test our hypothesis by using a clinically relevant orthotopic bladder model. Specific Aim 1 is to determine the effect of soybean components on orthotopic growth and/or metastasis of both well-differentiated, low metastatic (RT4) and poorly differentiated, highly metastatic (253J B-V) human bladder tumors. Soybean components (soy isoflavone-depleted soy protein, soy phytochemical concentrate, and soy genistin) will be evaluated for their effects on the growth and metastasis of both RT4 and 253J-B-V tumors in vivo. Specific aim 2 is to determine the effect of soybean components on the expression of tumor biomarkers that are related to tumor cell apoptosis and proliferation and tumor angiogenesis. These apoptotic and proliferation biomarkers include (a) apoptotic index and related apoptosis inducers (p53, p21/wafl, bax, TNF-alpha) and apoptosis repressors (bcl-2, bcl-xl), (b) proliferation index and cell cycle related cyclins (A, D, E) and cyclin-dependent kinases (cdks 2, 4, 6). Our in vitro microarray assays have suggested that markers that are related to angiogenesis network are among important genes that are significantly modulated by soy components. These angiogenic biomarkers include tumor angiogenic factors (VEGF, bFGF, angiopoietin-1) and anti-angiogenic factor angiopoietin-2. RT-PCR and immunohistochemistry followed by image analysis will be applied to determine the expression of above molecular markers. Specific aim 3 is to further elucidate mechanisms involved in the interactive affect of genes and soy bioactive components on bladder cancer modulation in vitro and in vivo by employing microarrayed cDNA chip technology. By using an oligonucleotide array containing sequences complementary to about 12,000 full-length human cDNAs, both dose-dependent and time-dependent mRNA expression patterns will be determined in both in vitro and in vivo samples. Some of these significantly different gene transcripts will be confirmed by RT-PCR. Results derived from the proposed studies by integrating nutrition, molecular biology and genetics in bladder cancer prevention research will be expected to provide significant insight into the utilization of dietary soy in the prevention of bladder cancer.
描述(由申请人提供):该提案的重点是大豆生物活性成分对膀胱癌的化学预防活性。该假设是,增加大豆生物活性成分的饮食消费可以作为一种有效的营养方案,用于通过调节膀胱肿瘤血管生成、凋亡和/或增殖来预防膀胱癌进展和转移。支持这一假设的基本原理是基于以下几点:(1)大豆生物活性成分通过血液循环和直接接触膀胱粘膜发挥其抗膀胱癌的作用,以及(2)我们的动物研究和体内机制研究表明,大豆植物化学物质通过诱导肿瘤细胞凋亡,抑制肿瘤增殖和抑制肿瘤血管生成来抑制膀胱肿瘤的进展。在这个建议中,三个具体的目标将被设计来测试我们的假设,通过使用临床相关的原位膀胱模型。具体目的1是确定大豆组分对高分化、低转移性(RT 4)和低分化、高转移性(253 J B-V)人膀胱肿瘤的原位生长和/或转移的影响。将评价大豆组分(大豆黄酮去除的大豆蛋白、大豆植物化学浓缩物和大豆染料木苷)对体内RT 4和253 J-B-V肿瘤生长和转移的影响。具体目标2是确定大豆组分对与肿瘤细胞凋亡和增殖以及肿瘤血管生成相关的肿瘤生物标志物表达的影响。这些凋亡和增殖生物标志物包括(a)凋亡指数和相关的凋亡诱导物(p53、p21/wafl、bax、TNF-α)和凋亡阻遏物(bcl-2、bcl-xl),(B)增殖指数和细胞周期相关的细胞周期蛋白(A、D、E)和细胞周期蛋白依赖性激酶(cdks 2、4、6)。我们的体外微阵列分析表明,与血管生成网络相关的标记物是受大豆成分显著调节的重要基因之一。这些血管生成生物标志物包括肿瘤血管生成因子(VEGF、bFGF、血管生成素-1)和抗血管生成因子血管生成素-2。采用RT-PCR和免疫组化结合图像分析的方法检测上述分子标志物的表达。具体目标3是通过微阵列cDNA芯片技术,进一步阐明基因和大豆生物活性成分在体外和体内对膀胱癌调控的相互作用机制。通过使用含有与约12,000个全长人cDNA互补的序列的寡核苷酸阵列,将在体外和体内样品中测定剂量依赖性和时间依赖性mRNA表达模式。这些显著不同的基因转录本中的一些将通过RT-PCR证实。通过将营养学、分子生物学和遗传学整合到膀胱癌预防研究中,从拟议的研究中获得的结果有望为利用膳食大豆预防膀胱癌提供重要的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JIN-RONG ZHOU其他文献
JIN-RONG ZHOU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JIN-RONG ZHOU', 18)}}的其他基金
Tanshinones for prevention of bladder cancer progression
丹参酮预防膀胱癌进展
- 批准号:
8296497 - 财政年份:2011
- 资助金额:
$ 30.26万 - 项目类别:
Targeting prostate cancer stem cells to delay prostate cancer progression
靶向前列腺癌干细胞以延缓前列腺癌进展
- 批准号:
8190865 - 财政年份:2011
- 资助金额:
$ 30.26万 - 项目类别:
Tanshinones for prevention of bladder cancer progression
丹参酮预防膀胱癌进展
- 批准号:
8203196 - 财政年份:2011
- 资助金额:
$ 30.26万 - 项目类别:
Targeting prostate cancer stem cells to delay prostate cancer progression
靶向前列腺癌干细胞以延缓前列腺癌进展
- 批准号:
8286889 - 财政年份:2011
- 资助金额:
$ 30.26万 - 项目类别:
Metabolic Syndrome as Pancreatic Cancer Etiology
代谢综合征作为胰腺癌的病因
- 批准号:
7469288 - 财政年份:2008
- 资助金额:
$ 30.26万 - 项目类别:
Metabolic Syndrome as Pancreatic Cancer Etiology
代谢综合征作为胰腺癌的病因
- 批准号:
7609157 - 财政年份:2008
- 资助金额:
$ 30.26万 - 项目类别:
Oldenlandia diffusa for prostate cancer treatment
白花蛇舌草治疗前列腺癌
- 批准号:
7314416 - 财政年份:2007
- 资助金额:
$ 30.26万 - 项目类别:
Parental metabolic status and offspring cancer risks
父母代谢状况和后代癌症风险
- 批准号:
7491579 - 财政年份:2007
- 资助金额:
$ 30.26万 - 项目类别:
Synergy between phytochemicals for prostate cancer prevention
植物化学物质之间的协同作用预防前列腺癌
- 批准号:
7322669 - 财政年份:2007
- 资助金额:
$ 30.26万 - 项目类别:
Oldenlandia diffusa for prostate cancer treatment
白花蛇舌草治疗前列腺癌
- 批准号:
7503961 - 财政年份:2007
- 资助金额:
$ 30.26万 - 项目类别:
相似国自然基金
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
- 批准号:81200692
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Elucidation of molecular mechanisms of angiogenesis mediated by angiopoietins and its application for asthma therapy
阐明血管生成素介导的血管生成的分子机制及其在哮喘治疗中的应用
- 批准号:
20590901 - 财政年份:2008
- 资助金额:
$ 30.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pilot--Angiopoietins 1 & 2 in colon cancer angiogenesis
试点--血管生成素1
- 批准号:
6563962 - 财政年份:2002
- 资助金额:
$ 30.26万 - 项目类别:
Pilot--Angiopoietins 1 & 2 in colon cancer angiogenesis
试点--血管生成素1
- 批准号:
6499812 - 财政年份:2001
- 资助金额:
$ 30.26万 - 项目类别:
Angiopoietins in airway vascular leak and angiogenesis
血管生成素在气道血管渗漏和血管生成中的作用
- 批准号:
6398138 - 财政年份:1998
- 资助金额:
$ 30.26万 - 项目类别:
Angiopoietins in airway vascular leak and angiogenesis
血管生成素在气道血管渗漏和血管生成中的作用
- 批准号:
6916548 - 财政年份:1998
- 资助金额:
$ 30.26万 - 项目类别:














{{item.name}}会员




